JP2005519891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519891A5 JP2005519891A5 JP2003559435A JP2003559435A JP2005519891A5 JP 2005519891 A5 JP2005519891 A5 JP 2005519891A5 JP 2003559435 A JP2003559435 A JP 2003559435A JP 2003559435 A JP2003559435 A JP 2003559435A JP 2005519891 A5 JP2005519891 A5 JP 2005519891A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- patient
- patients
- syndrome
- respiratory distress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000028399 Critical Illness Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34889002P | 2002-01-15 | 2002-01-15 | |
| PCT/US2003/000010 WO2003059270A2 (en) | 2002-01-15 | 2003-01-08 | Method for reducing morbidity and mortality in critically ill patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519891A JP2005519891A (ja) | 2005-07-07 |
| JP2005519891A5 true JP2005519891A5 (https=) | 2006-02-23 |
Family
ID=23370005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003559435A Pending JP2005519891A (ja) | 2002-01-15 | 2003-01-08 | 危篤状態の患者における罹病率および死亡率を低下させる方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050176631A1 (https=) |
| EP (1) | EP1469880A4 (https=) |
| JP (1) | JP2005519891A (https=) |
| AU (1) | AU2003201810A1 (https=) |
| CA (1) | CA2468610A1 (https=) |
| WO (1) | WO2003059270A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| EP2270163A1 (en) * | 2003-12-10 | 2011-01-05 | Eli Lilly and Company | Muteins of fibroblast growth factor 21 |
| US7622445B2 (en) | 2004-09-02 | 2009-11-24 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| KR100854198B1 (ko) | 2004-09-02 | 2008-08-26 | 일라이 릴리 앤드 캄파니 | 섬유아세포 성장 인자 21의 뮤테인 |
| EP2540696B1 (en) | 2005-02-24 | 2020-01-01 | Diffusion Pharmaceuticals LLC | Trans carotenoids, formulation and uses |
| CN107501407B (zh) | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
| US8034770B2 (en) | 2008-06-04 | 2011-10-11 | Amgen Inc. | FGF21 polypeptides comprising two or more mutations |
| CA2739615C (en) | 2008-10-10 | 2017-12-05 | Amgen Inc. | Fgf21 mutants comprising polyethylene glycol and uses thereof |
| WO2010129503A1 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| WO2010129600A2 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| MX2011013903A (es) * | 2009-06-17 | 2012-05-08 | Amgen Inc | Polipeptidos quimericos y usos de los mismos. |
| EP2445339B1 (en) | 2009-06-22 | 2019-08-07 | Diffusion Pharmaceuticals LLC | Diffusion enhancing compound and its use with a thrombolytic |
| EP2679234A3 (en) * | 2009-12-02 | 2014-04-23 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| CA2796055A1 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | Human fgf receptor and .beta.-klotho binding proteins |
| AU2011262361A1 (en) | 2010-06-02 | 2013-01-10 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
| JP2014500248A (ja) | 2010-11-05 | 2014-01-09 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗糖尿病化合物 |
| BR112014014898A2 (pt) | 2011-12-22 | 2020-10-27 | Pfizer Inc. | processo para purificar uma amostra de anticorpo h38c2, ou variante do mesmo, e composição compreendendo o referido h38c2 |
| CN114805532A (zh) | 2014-10-24 | 2022-07-29 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| CA3018550A1 (en) | 2016-03-24 | 2017-09-28 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
| SG11202001379WA (en) | 2017-09-08 | 2020-03-30 | Bristol Myers Squibb Co | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| JP2018135329A (ja) * | 2018-02-19 | 2018-08-30 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 双極性トランスカロテノイド塩及びそれらの使用 |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| EP3876996A1 (en) | 2018-11-05 | 2021-09-15 | Bristol-Myers Squibb Company | Method for purifying pegylated protein |
| EP4087612A1 (en) | 2020-01-08 | 2022-11-16 | Bristol-Myers Squibb Company | Fgf-21 conjugate formulations |
| JP2023538533A (ja) | 2020-08-07 | 2023-09-08 | ブリストル－マイヤーズ スクイブ カンパニー | 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１ |
| US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2163626A1 (en) * | 1999-11-18 | 2010-03-17 | Novartis Vaccines and Diagnostics, Inc. | Human FGF-21 gene and gene expression products |
| US6716626B1 (en) * | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| US20020081663A1 (en) * | 2000-01-05 | 2002-06-27 | Conklin Darrell C. | Novel FGF homolog ZFGF11 |
| AU2001245535A1 (en) * | 2000-03-08 | 2001-09-17 | Chiron Corporation | Human fgf-23 gene and gene expression products |
| US20020151496A1 (en) * | 2000-12-08 | 2002-10-17 | Bringmann Peter W. | Novel fibroblast growth factors |
| US20040259780A1 (en) * | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
-
2003
- 2003-01-08 US US10/499,608 patent/US20050176631A1/en not_active Abandoned
- 2003-01-08 JP JP2003559435A patent/JP2005519891A/ja active Pending
- 2003-01-08 CA CA002468610A patent/CA2468610A1/en not_active Abandoned
- 2003-01-08 AU AU2003201810A patent/AU2003201810A1/en not_active Abandoned
- 2003-01-08 WO PCT/US2003/000010 patent/WO2003059270A2/en not_active Ceased
- 2003-01-08 EP EP03700669A patent/EP1469880A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519891A5 (https=) | ||
| JP2003526626A5 (https=) | ||
| JP2007514005A5 (https=) | ||
| JP2006503588A5 (https=) | ||
| JP2003503454A5 (https=) | ||
| JP2007514637A5 (https=) | ||
| ES2178943A1 (es) | Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica. | |
| WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
| NO20013988L (no) | Kombinasjoner av formoterol og mometasonfuroat mot astma | |
| JP2003520232A5 (https=) | ||
| JP2010534236A5 (https=) | ||
| JP2006507281A5 (https=) | ||
| NO20013460D0 (no) | Kombinasjoner av formoterol og et tiotropiumsalt | |
| JP2012512699A5 (https=) | ||
| FI3457135T3 (fi) | Fabryn taudin hoitovaihtoehtoja | |
| JP2004002446A5 (https=) | ||
| JP2007520565A5 (https=) | ||
| JP2005508963A5 (https=) | ||
| JP2008513510A5 (https=) | ||
| WO2005011614A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease | |
| JP2020516689A5 (https=) | ||
| EP2158901A3 (en) | Alpha aztreonam lysinate | |
| WO2002017894A3 (en) | Pharmaceutical formulation of salmeterol and fluticasone propionate | |
| JP2008513426A5 (https=) | ||
| JP2002326936A5 (https=) |